SCHEMBL10021888

CCCCCCCCCCCCC/C=C/[C@@H](O)[C@H](CO[C@@H]1OC(CO)[C@@H](O[C@@H]2OC(CO)[C@H](O[C@@H]3OC(CO)[C@H](O)[C@H](O[C@@H]4OC(CO)[C@H](O)[C@H](O)C4O)C3C)[C@H](O[C@]3(OC=O)C[C@@H](O)[C@@H](C)C([C@H](O)[C@H](O)CO)O3)C2O)[C@H](O)C1O)NC(=O)CCCCCCCCCCCCCCC

nearest known ligand 0.53

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	SELP	P16109	12/20	0.53

▸	APP	P05067	1/20	0.43

▸	SELL	P14151	1/20	0.40

▸	CETP	P11597	1/20	0.40

▸	SIGLEC7	Q9Y286	2/20	0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL17789071	0.98	SELP (0.54)	SELPAPPSELLCETPSIGLEC7
SCHEMBL10021894	0.97	SELP (0.53)	SELPAPPSELLCETPSIGLEC7
SCHEMBL10021896	0.97	SELP (0.51)	SELPAPPSELLCETPSIGLEC7
SCHEMBL10021889	0.97	SELP (0.55)	SELPAPPSELLCETPSIGLEC7
SCHEMBL10021893	0.96	SELP (0.57)	SELPAPPSELLCETPSIGLEC7
SCHEMBL17789069	0.95	SELP (0.51)	SELPAPPSELLCETPSIGLEC7
SCHEMBL17789070	0.95	SELP (0.51)	SELPAPPSELLCETPSIGLEC7
SCHEMBL17789072	0.95	SELP (0.51)	SELPAPPSELLCETPSIGLEC7
SCHEMBL10021891	0.93	SELP (0.53)	SELPAPPSELLCETPSIGLEC7
SCHEMBL10021892	0.92	SELP (0.61)	SELPAPPCETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20160151401-A1	GLYCOLIPIDS AS TREATMENT FOR DISEASE	LA JOLLA PHARMACEUTICAL COMPANY	2016-06-02	—	—	US	disclosed
US-20120035120-A1	GLYCOLIPIDS AS TREATMENT FOR DISEASE	SENEB BIOSCIENCES, INC. (US)	2012-02-09	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120035120-A1	GLYCOLIPIDS AS TREATMENT FOR DISEASE	GBA2, UGCG, GBA1	SELP 2417/4885APP 720/4885SELL 2166/4885
US-20160151401-A1	GLYCOLIPIDS AS TREATMENT FOR DISEASE	GBA2, UGCG, GBA1	SELP 2417/4885APP 720/4885SELL 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.